Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Impact of a Web-based Empowerment Program on Intolerance of Uncertainty and Maintenance Burden.

19. juni 2026 opdateret af: Kübra Nur KÖSE ALABAY, Necmettin Erbakan University

The Effect of a Web-Based Empowerment Program Based on the Theory of Illness Applied to Caregivers of Prostate Cancer Patients on Intolerance of Uncertainty and Caregiver Burden: A Randomized Controlled Trial

The aim of this study is to examine the relationship between uncertainty intolerance and caregiver burden in a web-based empowerment program based on uncertainty theory in disease, applied to caregivers of prostate cancer patients.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study was designed as a pre-test-post-test parallel-group, randomized controlled experimental design. The research will be conducted at the Radiation Oncology Clinic of Necmettin Erbakan University Faculty of Medicine Hospital, Republic of Turkey. Caregivers of prostate cancer patients will be randomly divided into two groups: experimental group (31) and control group (31). For the experimental group: A web-based reinforcement program based on uncertainty theory will be applied. For the control group: No application will be made to the caregivers. The primary outcome of this study is to determine the intolerance to uncertainty scores of caregivers of prostate cancer patients. The secondary outcome is to determine the caregiving burden of caregivers.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

62

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Over 18 years of age,
  • Able to speak Turkish,
  • Literate,
  • No hearing or vision problems,
  • No neurological and/or psychiatric disorders,
  • Physical and cognitive health levels suitable for answering the forms used in the study,
  • Having a patient diagnosed with prostate cancer,
  • Being the primary caregiver responsible for meeting the patient's care needs (home care, supervision, hospital check-ups, etc.) within the family,
  • Having a patient scheduled for hormone therapy and radiotherapy,
  • Not having undergone prostatectomy,
  • Having an electronic device such as a smartphone or computer with internet access, either themselves or a family member,
  • Caregivers of prostate cancer who volunteer to participate in the study will be included.

Exclusion Criteria:

  • Caregivers whose patients are receiving chemotherapy will be excluded.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Strengthening Program Group
Caregivers will participate in a 15-week Web-Based Caregiver Empowerment Program. In the first week, after completing an informed consent form, caregivers will be introduced to the Web-Based Empowerment Program based on the Theory of Illness. Pre-test forms (Caregiver Information Form, Intolerance of Uncertainty Scale (IUS-12), Zarit Caregiver Burden Scale) will be administered. The program will include two modules of training and five counseling sessions for caregivers. In the second week, caregivers will receive training on Module 1: General Information about Prostate Cancer and Hormone Therapy in Prostate Cancer. In the seventh week, training on Module 2: Radiotherapy in Prostate Cancer will be provided. Counseling sessions will be held in weeks three, five, eight, eleven, and thirteen. During the counseling session, patients' questions regarding the training will be answered. The final test forms (Caregiver Information Form, Intolerance of Uncertainty Scale (IUS-12), Zarit Caregiv
Andet: Web-Based Empowerment Program Based on Uncertainty Theory
Web-Based Empowerment Program Based on Uncertainty Theory
Ingen indgriben: Control
Caregivers will not receive any intervention for fifteen weeks. Standard care will be provided. In the first week, caregivers will be administered pre-test forms (Caregiver Information Form, Intolerance of Uncertainty Scale (IUS-12), Zarit Caregiver Burden Scale form). In the fifteenth week, post-test forms (Caregiver Information Form, Intolerance of Uncertainty Scale (IUS-12), Zarit Caregiver Burden Scale form) will be administered.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Intolerance of Uncertainty Scale
Tidsramme: first week and fifteenth week
The highest possible score on the scale is 60, and the lowest is 12. Higher scores indicate a high level of intolerance for uncertainty. Higher scores indicate greater intolerance for uncertainty.
first week and fifteenth week

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Zarit Caregiver Burden Scale
Tidsramme: first week and fifteenth week
The scale can be scored from a minimum of 0 to a maximum of 88 points. A high score on the scale indicates a high caregiver burden.
first week and fifteenth week

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Necmettin Erbakan University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. juli 2026

Primær færdiggørelse (Anslået)

12. april 2027

Studieafslutning (Anslået)

17. maj 2027

Datoer for studieregistrering

Først indsendt

19. juni 2026

Først indsendt, der opfyldte QC-kriterier

19. juni 2026

Først opslået (Faktiske)

25. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • Nec Erbakan U

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner